Navigation Links
New insights into facial transplantation
Date:1/17/2014

Boston, MAIn 2009, the first face transplant was performed at Brigham and Women's Hospital (BWH), and lead surgeon, Dr. Bohdan Pomahac has been pioneering the procedure since. However, understanding the technical challenges, particularly around how the recipient accepts or rejects the donated face, is just beginning. Following any transplant, including facial transplant, T cells in the recipient mount an immune response to the donated tissue, threatening rejection. This process is successfully managed through immunosupression medication so that the recipient is able to tolerate the transplanted face. Now, researchers at BWH have made a discovery that provides new insight into the body's rejection process. Researchers have demonstrated that immune cells, or T cells, involved in the rejection process are significantly of donor origin. These findings are published in Modern Pathology on January 17, 2014.

"The conventional belief about face transplant was that rejection is directly related to the recipient T cells attacking the donor T cells of the face, which are perceived as foreign to the recipient's immune system," explained Christine Lian, MD, a skin pathologist at BWH and lead author of this study. "We now need to rethink this process. Based on our findings, it is clear that the donor T cells, which are transferred as part of the new face, play a significant role in the rejection process as well."

The researchers examined 131 face transplant biopsy specimens from a total of five patients who received a face transplant between 2009 and 2013 at BWH. The samples were examined by conventional microscopy for categorizing the level of rejection and guiding immunosuppressant therapy, and additional antibody based biomarkers were also applied. The use of biomarkers allowed the researchers to differentiate between the donor and recipient cells under the microscope. Researchers found that during active rejection episodes, many to most o
'/>"/>

Contact: Jessica Maki
jmaki3@partners.org
617-525-6373
Brigham and Women's Hospital
Source:Eurekalert

Page: 1 2

Related biology news :

1. Elephant shark genome provides new insights into bone formation and adaptive immunity in humans
2. Study led by NUS scientists provides new insights into cause of human neurodegenerative disease
3. Oregon scientists offer new insights on controlling nanoparticle stability
4. New insights into the immune system of the gastrointestinal tract
5. New insights into cancer evolution help define screening window of opportunity
6. A study on cell migration provides insights into the movement of cancer cells
7. Global map provides new insights into land use
8. Physicists provide new insights into coral skeleton formation
9. New insights into DNA repair process may spur better cancer therapies
10. Erratic proteins: New insights into a transport mechanism
11. Eyewear Market 2014 Insights and System Refresher Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2015)... TRIANGLE PARK, North Carolina , 5. ... sein 35. Jahr als spezialisiertes Logistikunternehmen und ... Position als einzige klinische Logistikfirma (Clinical Logistics ... Die Kernbotschaft der neuen Kampagne lautet ... und Lieferungen. Foto: http://photos.prnewswire.com/prnh/20150205/173753 ...
(Date:2/5/2015)... SAN FRANCISCO , January 28, 2015 ... Camera Market Analysis, Size And Segment Forecasts To 2020 ... The global IR camera market is expected to reach ... study by Grand View Research, Inc. IR cameras help ... injuries, and are expected to witness surging demand in ...
(Date:1/22/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced ... Overview" report to their offering. , ... an individual is who she/he is claiming to be, and ... person,s unique physical characteristics, such as fingerprint, hand or palm ...
Breaking Biology News(10 mins):Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 2IR Camera Market Worth $5.10 Billion By 2020: Grand View Research, Inc. 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... so indelibly that their children are affected. History ... starvation, whose children experience altered physiology. Now ... University have found an instance of animals passing ... to their offspring. That information comes not through ...
... mapping how proteins interact with each other, developed at ... the design of new drugs for diseases such as ... acids, the Salk scientists determine the detailed molecular structure ... that turns it on. The switch--corticotrophin releasing factor type ...
... 29 November 2013 The American Association for the Advancement ... Science Policy Programme at EMBO, to its 2013 class of ... upon AAAS members by their peers and acknowledges contributions that ... been recognized by AAAS for her work looking at the ...
Cached Biology News:Mice can inherit learned sensitivity to a smell 2Mice can inherit learned sensitivity to a smell 3Salk scientists crack riddle of important drug target 2Salk scientists crack riddle of important drug target 3
(Date:2/27/2015)...  Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology ... announced that it will be presenting at CALBIO 2015 ... nd at 3pm PST. Patrick Lucy, chief business officer ... current state of the biosimilar industry landscape entitled ... For more information on CALBIO 2015 and The ...
(Date:2/27/2015)... CA (PRWEB) February 27, 2015 Cytokinetics, ... forces on February 28 with patients and health care ... awareness for Rare Disease Day®. Rare Disease Day ... and calling attention to the special challenges faced by ... them. , “Cytokinetics is proud to stand alongside patients ...
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , a ... and commercializing disruptive products and technologies in the healthcare ... , former CEO and Member of the Board of ... "It,s has been a pleasure to know ... that we will be working together more closely now," ...
(Date:2/26/2015)... 26, 2015 On behalf of biotech client ... Wilentz, Goldman & Spitzer, P.A. (Wilentz) secured a ... Genewiz Inc. in excess of $10 million. The jury ... secrets, and that it improperly hired one or more ... motions for judgment notwithstanding the verdict, a new trial, ...
Breaking Biology Technology:Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... and VANCOUVER, Feb. 4 /PRNewswire-FirstCall/ - OncoGenex Pharmaceuticals, Inc. ... survival rate from a Phase 1/2 clinical trial of ... of advanced non-small cell lung cancer (NSCLC). At two ... first-line chemotherapy were alive. OncoGenex has previously reported a ...
... introduction to the benefits of Shape Memory Alloys. The Kit is a ... a comprehensive manual, and easy to follow demonstrations on the morphing abilities ... ... -- Imagine a future where the only tool in an auto body ...
... HUNTINGTON BEACH, California and AMSTERDAM, February 4 ... diagnostics, today announced that,its signature breast cancer ... of,care for all eligible early stage breast ... Leeuwenhoek Hospital (NKI-AVL). The NKI-AVL,believes MammaPrint provides ...
Cached Biology Technology:OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 2OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 3OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 4OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer 5Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 2Re-Shaping the Future with Shape Memory Alloys - SMA Starter Kit 3Agendia's Breast Cancer Test MammaPrint(R) Standard of Care at Netherlands Cancer Institute - AVL 2
This SMAD antibody sampler pack contains 5 Polyclonal ,SMAD antibodies....
Phosphate-Buffered Saline (PBS) 7.4 (1X) liquid...
... Rat Antibody to Human CD66 ... is expressed by human neutrophils and ... carcinoma. Clone YTH71.3 reacts with transfectants ... are CEA subfamily members(2). ...
... GOAT ANTI-MOUSE IgG+IgA+IgM (H+L) ... with highly purified horseradish ... antibody has been absorbed ... fetal bovine, horse, goat, ...
Biology Products: